Clinical-stage pharmaceutical company developing oral iron chelators to treat systemic and local iron overload
Clinical-stage pharmaceutical company developing oral iron chelators to treat systemic and local iron overload. Its lead brain-penetrant small molecule, SP-420, has been studied for transfusion-related iron overload and iron accumulation associated with age-related macular degeneration and neurological disease. AbFero was acquired by Pharmacosmos.